Retraction: Catestatin increases the expression of anti-apoptotic and pro-angiogenetic factors in the post-ischemic hypertrophied heart of shr (PLoS ONE (2014) 9: 8 (e102536) DOI: 10.1371/journal.pone.0102536);Catestatin increases the expression of anti-apoptotic and pro-angiogenetic factors in the post-ischemic hypertrophied heart of SHR

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Penna, Claudia ^a   Pasqua, Teresa ^b   Amelio, Daniela ^b   Perrelli, Maria Giulia ^a   Angotti, Carmelina ^a   Tullio, Francesca ^a   Mahata, Sushil K ^c   Tota, Bruno ^b,d   Pagliaro, Pasquale ^a,d   Cerra, Maria C ^b,d   Angelone, Tommaso ^b,d  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d National Institute for Cardiovascular Research   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; CATESTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; APOPTOSIS REGULATORY PROTEIN; CHROMOGRANIN A; CHROMOGRANIN A (344-364); PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART HYPERTROPHY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HYPERTENSION; MALE; NITROSYLATION; NONHUMAN; PHOSPHORYLATION; RAT; REPERFUSION INJURY; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT; ANIMAL; BIOSYNTHESIS; CARDIOMEGALY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; HEART MUSCLE; METABOLISM; MYOCARDIAL ISCHEMIA; PATHOLOGY;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CARDIOMEGALY; CHROMOGRANIN A; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR;

EID: 84905457101     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0246900     Document Type: Erratum

References (50)

1. Ferdinandy P, Schulz R, Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418-458. doi:10.1124/pr.107.06002.
2. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, et al. (2008) Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res: 102: 131-135. doi:10.1161/CIRCRESAHA.107.164699.
3. Oikawa M, Yaoita H, Watanabe K, Maruyama Y (2008) Attenuation of cardioprotective effect by postconditioning in coronary stenosed rat heart and its restoration by carvedilol. Circ J 72: 2081-2086. doi.org/10.1253/circj.CJ- 08-0098.
4. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004) Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95: 230-232. (Pubitemid 39056282)
5. Penna C, Tullio F, Moro F, Folino A, Merlino A, et al. (2010) Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats. Basic Res Cardiol 105: 181-192. doi:10.1007/s00395-009-0075-6.
6. Wagner C, Ebner B, Tillack D, Strasser RH, Weinbrenner C (2013) Cardioprotection by ischemic postconditioning is abrogated in hypertrophied myocardium of spontaneously hypertensive rats. J Cardiovasc Pharmacol 61: 35-41. doi:10.1097/FJC.0b013e3182760c4d.
7. Fantinelli JC, Pérez Núñez IA, González Arbeláez LF, Schinella GR, Mosca SM, et al. (2013) Participation of mitochondrial permeability transition pore in the effects of ischemic preconditioning in hypertrophied hearts: Role of NO and mitoK(ATP). Int J Cardiol 166: 173-180. doi:10.1016/j.ijcard.2011.10.103.
8. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, et al. (2008) The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 149: 4780-4793. doi:10.1210/en.2008-0318.
9. Bassino E, Fornero S, Gallo MP, Ramella R, Mahata SK, et al. (2011) A novel catestatin-induced antiadrenergic mechanism triggered by the endothelial PI3KeNOS pathway in the myocardium. Cardiovasc Res 91: 617-624. doi:10.1093/cvr/cvr129.
10. Angelone T, Mazza R, Cerra MC (2012) Chromogranin-A: a multifaceted cardiovascular role in health and disease. Curr Med Chem 19: 4042-4050. DOI:10.2174/092986712802430009.
11. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, et al. (2002) Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20: 1335-1345. (Pubitemid 34925678)
12. Biswas N, Curello E, O'Connor DT, Mahata SK (2010) Chromogranin/ secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell Tissue Res 342: 353-361. doi:10.1007/s00441-010-1059-4.
13. Angelone T, Quintieri AM, Pasqua T, Gentile S, Tota B, et al. (2012) Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin. Am J Physiol Heart Circ Physiol 302: H431-H442. doi:10.1152/ajpheart.00491.2011.
14. Theurl M, Schgoer W, Albrecht K, Jeschke J, Egger M, et al. (2010) The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res 107: 1326-1335. doi:10.1161/CIRCRESAHA.110.219493.
15. Penna C, Alloatti G, Gallo MP, Cerra MC, Levi R, et al. (2010) Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol 30: 1171-1179. doi:10.1007/s10571-010-9598-5.
16. Perrelli MG, Tullio F, Angotti C, Cerra MC, Angelone T, et al. (2013) Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial K(ATP) channels and ROS signalling. Pflugers Arch 465: 1031-1040. doi:10.1007/s00424-013-1217-0.
17. Penna C, Perrelli MG, Tullio F, Moro F, Parisella ML, et al. (2011) Postischemic early acidosis in cardiac postconditioning modifies the activity of antioxidant enzymes, reduces nitration, and favors protein S-nitrosylation. Pflugers Arch. 462: 219-233. doi:10.1007/s00424-011-0970-1.
18. Murphy E, Kohr M, Sun J, Nguyen T, Steenbergen C (2012) S-nitrosylation: a radical way to protect the heart. J Mol Cell Cardiol 52: 568-577. doi:10.1016/j.yjmcc.2011.08.021.
19. Pagliaro P, Moro F, Tullio F, Perrelli MG, Penna C (2011) Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid Redox Signal 14: 833-850. doi:10.1089/ars.2010.3245.
20. Lim SY, Hausenloy DJ, Arjun S, Price AN, Davidson SM, et al. (2011) Mitochondrial cyclophilin-D as a potential therapeutic target for postmyocardial infarction heart failure. J Cell Mol Med 15: 2443-2451. doi:10.1111/j.1582- 4934.2010.01235.x.
21. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, et al. (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115: 2108-2118. doi:10.1172/JCI24682. (Pubitemid 41134152)
22. Ong SG, Hausenloy DJ (2012) Hypoxia-inducible factor as a therapeutic target for cardioprotection. Pharmacol Ther 136: 69-81. doi:10.1016/j. pharmthera.2012.07.005.
23. Sen S, Tarazi RC, Khairallah PA, Bumpus FM (1974) Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 35: 775-781. doi:10.1161/01.RES.35.5. 775.
24. Heusch G (2012) HIF-1a and paradoxical phenomena in cardioprotection. Cardiovasc Res 96: 214-215. doi:10.1093/cvr/cvs145.
25. De Francesco EM, Angelone T, Pasqua T, Pupo M, Cerra MC, et al. (2013) GPER mediates cardiotropic effects in spontaneously hypertensive rat hearts. PLoSOne 8: e69322. doi:10.1371/journal.pone.0069322.
26. Pagliaro P, Mancardi D, Rastaldo R, Penna C, Gattullo D, et al. (2003) Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med 34: 33-43. doi.org/10.1016/S0891-5849(02) 01179-6. (Pubitemid 36043884)
27. Penna C, Alloatti G, Cappello S, Gattullo D, Berta G, et al. (2005) Plateletactivating factor induces cardioprotection in isolated rat heart akin to ischaemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation. Am J Physiol Heart Circ Physiol 288: H2512-H2520. DOI:10.1152/ajpheart.00599.2004. (Pubitemid 40604141)
28. Penna C, Pasqua T, Perrelli MG, Pagliaro P, Cerra MC, et al. (2012) Postconditioning with glucagon like peptide-2 reduces ischemia/reperfusion injury in isolated rat hearts: role of survival kinases and mitochondrial KATP channels. Basic Res Cardiol 107: 272. doi:10.1007/s00395-012-0272-6.
29. Sumi S, Kobayashi H, Yasuda S, Iwasa M, Yamaki T, et al. (2010) Postconditioning effect of granulocyte colony-stimulating factor is mediated through activation of risk pathway and opening of the mitochondrial KATP channels. Am J Physiol Heart Circ Physiol 299: H1174-H1182. doi:10.1152/ ajpheart.00116.2010.
30. Faghihi M, Alizadeh AM, Khori V, Latifpour M, Khodayari S (2012) The role of nitric oxide, reactive oxygen species, and protein kinase C in oxytocin-induced cardioprotection in ischemic rat heart. Peptides 37: 314-319. doi:10.1016/j.peptides.2012.08.001.
31. Quadrilatero J, Bloemberg D (2010) Apoptosis repressor with caspase recruitment domain is dramatically reduced in cardiac, skeletal, and vascular smooth muscle during hypertension. Biochem Biophys Res Commun 391: 1437-1442. doi:10.1016/j.bbrc.2009.12.084.
32. Amelio D, Garofalo F, Wong WP, Chew SF, Ip YK, et al. (2013) Nitric oxide synthase-dependent "On/Off" switch and apoptosis in freshwater and aestivating lungfish, Protopterus annectens: Skeletal muscle versus cardiac muscle. Nitric Oxide 32: 1-12. doi:10.1016/j.niox.2013.03.005.
33. Li Y, Ge X, Liu X (2009) The cardioprotective effect of postconditioning is mediated by ARC through inhibiting mitochondrial apoptotic pathway. Apoptosis 14: 164-172. doi:10.1007/s10495-008-0296-4.
34. Penna C, Perrelli MG, Raimondo S, Tullio F, Merlino A, et al. (2009) Postconditioning induces an anti-apoptotic effect and preserves mitochondrial integrity in isolated rat hearts. Biochim Biophys Acta 1787: 794-801. doi:10.1016/j.bbabio.2009.03.013.
35. Zhao HX, Wang XL, Wang YH, Wu Y, Li XY, et al. (2010) Attenuation of myocardial injury by postconditioning: role of hypoxia inducible factor-1alpha. Basic Res Cardiol 105: 109-118. doi:10.1007/s00395-009-0044-0.
36. Jugdutt BI (2002) Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev 7: 391-405.
37. Amelio D, Garofalo F, Brunelli E, Loong AM, Wong WP, et al. (2008) Differential NOS expression in freshwater and aestivating Protopterus dolloi (lungfish): heart vs kidney readjustments. Nitric Oxide 18: 1-10. doi.org/10.1016/j.niox.2007.10.004.
38. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 7: 248-254.
39. 2+ channel alpha1 subunit and reduced ischemia/reperfusion injury. Circ Res 98: 403-411. doi:10.1161/01.RES.0000202707.79018.0a.
40. Mahata SK, Mahata M, Wakade AR, O'Connor DT (2000) Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364): Identification of amino acid residues crucial for activity. Mol Endocrinol 14: 1525-1535.
41. Salloum FN, Das A, Samidurai A, Hoke NN, Chau VQ, et al. (2012) Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol 302: H1347-H1354. doi:10.1152/ajpheart.00544.2011.
42. Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, et al. (2005) Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 67: 124-133. doi:10.1016/j.cardiores. 2005.02.015.
43. Penna C, Tullio F, Perrelli MG, Moro F, Abbadessa G, et al. (2011) Ischemia/reperfusion injury is increased and cardioprotection by a postconditioning protocol is lost as cardiac hypertrophy develops in nandrolone treated rats. Basic Res Cardiol 106: 409-420. doi:10.1007/s00395-010-0143-y.
44. Hua Y, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, et al. (2011) Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res Cardiol. 106: 1173-1191. doi:10.1007/s00395-011-0222-8.
45. Braz JC, Gill RM, Corbly AK, Jones BD, Jin N, et al. (2009) Selective activation of PI3Kalpha/Akt/GSK-3beta signalling and cardiac compensatory hypertrophy during recovery from heart failure. Eur J Heart Fail 11: 739-748. doi:10.1093/eurjhf/hfp094.
46. Velez Rueda JO, Palomeque J, Mattiazzi A (2012) Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensin system activity involves CaMKII. J Appl Physiol 112: 2110-2120. doi:10.1152/ japplphysiol.01383.2011.
47. Zorov DB, Juhaszova M, Yaniv Y, Nuss HB, Wang S, et al. (2009) Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res 83: 213-225. doi:10.1093/cvr/cvp151.
48. Koseki T, Inohara N, Chen S, Núñez G (1998) ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc Natl Acad Sci USA 95: 5156-5560.
49. Zhao HX, Wang XL, Wang YH, Wu Y, Li XY, et al. (2010) Attenuation of myocardial injury by postconditioning: role of hypoxia inducible factor-1alpha. Basic Res Cardiol 105: 109-118. doi:10.1007/s00395-009-0044-0.
50. Pasqua T, Corti A, Gentile S, Pochini L, Bianco M, et al. (2013) Full-length human Chromogranin-A cardioactivity: myocardial, coronary and stimulusinduced processing evidence in normotensive and hypertensive male rat hearts. Endocrinology 154: 3353-3365. doi:10.1210/en.2012-2210. Ricerca